By Elias Schisgall
Shares of Turn Therapeutics climbed ahead of the company's release of initial findings from a phase 2 trial of GX-03, its treatment for atopic dermatitis.
Shares were up 2.9%, to $7.91, in after-hours trading Monday. The stock closed up 8%, at $7.69, having nearly doubled in value this year.
The company said Monday that it would present findings from an initial analysis of data from the study on a Tuesday webcast. It would also share an optimized study design for the remaining stage of the phase 2 trial.
Write to Elias Schisgall at elias.schisgall@wsj.com